Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ren Fail. 2022 Dec;44(1):2037-2045. doi: 10.1080/0886022X.2022.2147673.
To explore the clinicopathological features of anti-glomerular basement membrane (anti-GBM) glomerulonephritis (anti-GBM-GN) and the prognostic values of clinical and laboratory indicators at diagnosis on renal and patient survival.
A total of 76 patients (34 males and 42 females) with anti-GBM-GN who were hospitalized in the First Affiliated Hospital of Nanjing Medical University between January 2010 and June 2021 were included in this study. The baseline clinical features, histopathological data from renal biopsies, and predictors of renal and patient survival were retrospectively analyzed.
Among the 76 patients, the median serum creatinine at diagnosis was 618.0 (350.98, 888.25) μmol/L and the median estimated glomerular filtration rate (eGFR) was 6.62 (4.39, 14.41) mL/min. Of these 76 patients, 55 (72.4%) received initial kidney replacement therapy (KRT) and 39 (51.3%) received plasma exchange or double-filtered plasmapheresis (DFPP). During a median follow-up duration of 28.5 (6.0, 71.8) months, 53 (69.7%) patients progressed to kidney failure with replacement therapy (KFRT) and received maintenance dialysis. Initial KRT (HR = 3.48, 95% CI = 1.22-9.97, = 0.020) was a significant risk factor for renal survival. During the follow-up, 49 (64.5%) of 76 patients survived. Age (≥60 years, HR = 4.13, 95% CI = 1.65-10.38, = 0.003) and initial KRT (HR = 2.87, 95% CI = 1.01-8.14, = 0.047) were predictive of patient survival.
Among patients with anti-GBM-GN, initial KRT at presentation was predictive of KFRT while older age and initial KRT were associated with higher all-cause mortality.
探讨抗肾小球基底膜(anti-glomerular basement membrane,anti-GBM)肾小球肾炎(glomerulonephritis,anti-GBM-GN)的临床病理特征,以及诊断时的临床和实验室指标对肾脏和患者生存的预后价值。
回顾性分析 2010 年 1 月至 2021 年 6 月期间在南京医科大学第一附属医院住院的 76 例抗-GBM-GN 患者(34 例男性和 42 例女性)的基线临床特征、肾活检的组织病理学数据以及肾脏和患者生存的预测因素。
76 例患者中,诊断时血清肌酐中位数为 618.0(350.98,888.25)μmol/L,估算肾小球滤过率(estimated glomerular filtration rate,eGFR)中位数为 6.62(4.39,14.41)mL/min。其中 55 例(72.4%)患者接受初始肾脏替代治疗(kidney replacement therapy,KRT),39 例(51.3%)患者接受血浆置换或双重滤过血浆置换(double-filtered plasmapheresis,DFPP)。中位随访时间为 28.5(6.0,71.8)个月,53 例(69.7%)患者进展为需要替代治疗的肾衰竭(kidney failure with replacement therapy,KFRT)并接受维持性透析。初始 KRT(hazard ratio,HR=3.48,95% confidence interval,CI=1.22-9.97, = 0.020)是肾脏生存的显著危险因素。在随访期间,76 例患者中有 49 例(64.5%)存活。年龄(≥60 岁,HR=4.13,95%CI=1.65-10.38, = 0.003)和初始 KRT(HR=2.87,95%CI=1.01-8.14, = 0.047)是患者生存的预测因素。
在抗-GBM-GN 患者中,发病时的初始 KRT 预测 KFRT,而年龄较大和初始 KRT 与全因死亡率升高相关。